Acute Ischemic Stroke Severity, Progression, and Outcome Relate to Changes in Dipeptidyl Peptidase IV and Fibroblast Activation Protein Activity

Translational Stroke Research

Volumn 8, Issue 2, 2017, Pages 157-164

  Baerts, Lesley ^a   Brouns, Raf ^b,c   Kehoe, Kaat ^a   Verkerk, Robert ^a   Engelborghs, Sebastiaan ^d,e   De Deyn, Peter Paul ^d,e   Hendriks, Dirk ^a   De Meester, Ingrid ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^c VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^d UNIVERSITY OF ANTWERP   (Belgium)

^e Hospital Network Antwerp ZNA Middelheim and Hoge Beuken   (Belgium)

Author keywords

Acute ischemic stroke; Dipeptidyl peptidase IV (DPP IV); Fibroblast activation protein (FAP); Stroke evolution; Stroke outcome; Stroke severity

Indexed keywords

C REACTIVE PROTEIN; DIPEPTIDYL PEPTIDASE IV; FIBROBLAST ACTIVATION PROTEIN; SERINE PROTEINASE; UNCLASSIFIED DRUG; DPP4 PROTEIN, HUMAN; GELATINASE; MEMBRANE PROTEIN; SEPRASE;

AGED; ALCOHOL ABUSE; ARTICLE; ATRIAL FIBRILLATION; BLOOD SAMPLING; BRAIN ISCHEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISABILITY; DISEASE COURSE; DISEASE SEVERITY; DYSLIPIDEMIA; ENZYME ACTIVITY; FAMILY HISTORY; FEMALE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART INFARCTION; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; MALE; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; OUTCOME ASSESSMENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; SMOKING; STROKE PATIENT; SYSTOLIC BLOOD PRESSURE; BLOOD; ENZYMOLOGY; SEVERITY OF ILLNESS INDEX; STROKE;

AGED; BRAIN ISCHEMIA; DIPEPTIDYL PEPTIDASE 4; DISEASE PROGRESSION; FEMALE; GELATINASES; HUMANS; MALE; MEMBRANE PROTEINS; SERINE ENDOPEPTIDASES; SEVERITY OF ILLNESS INDEX; STROKE;

EID: 84983454417     PISSN: 18684483     EISSN: 1868601X     Source Type: Journal    
DOI: 10.1007/s12975-016-0493-3     Document Type: Article

References (28)

1. Darsalia V, Ortsäter H, Olverling A, Darlöf E, Wolbert P, Nyström T, Klein T, Sjöholm Å, Patrone C. The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride. Diabetes. 2013;62:1289–96.
2. Monami M, Ahrén B, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2013;15:112–20.
3. Shannon RP. DPP-4 inhibition and neuroprotection: do mechanisms matter? Diabetes. 2013;62:1029–31.
4. Robin AM, Zhang ZG, Wang L, Zhang RL, Katakowski M, Zhang L, Wang Y, Zhang C, Chopp M. Stromal cell-derived factor 1alpha mediates neural progenitor cell motility after focal cerebral ischemia. J Cereb Blood Flow Metab. 2006;26:125–34.
5. Paczkowska E, Kucia M, Koziarska D, et al. Clinical evidence that very small embryonic-like stem cells are mobilized into peripheral blood in patients after stroke. Stroke. 2009;40:1237–44.
6. Rost NS, Biffi A, Cloonan L, Chorba J, Kelly P, Greer D, Ellinor P, Furie KL. Brain natriuretic peptide predicts functional outcome in ischemic stroke. Stroke. 2012;43:441–5.
7. Keane FM, Nadvi NA, Yao T-W, Gorrell MD. Neuropeptide Y, B-type natriuretic peptide, substance P and peptide YY are novel substrates of fibroblast activation protein-α. FEBS J. 2011;278:1316–32.
8. Röhnert P, Schmidt W, Emmerlich P, et al. Dipeptidyl peptidase IV, aminopeptidase N and DPIV/APN-like proteases in cerebral ischemia. J Neuroinflammation. 2012;9:44.
9. Matheeussen V, Jungraithmayr W, De Meester I. Dipeptidyl peptidase 4 as a therapeutic target in ischemia/reperfusion injury. Pharmacol Ther. 2012;136:267–82.
10. Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of org 10172 in acute stroke treatment. Stroke. 1993;24:35–41.
11. Brouns R, Heylen E, Willemse JL, Sheorajpanday R, De Surgeloose D, Verkerk R, De Deyn PP, Hendriks DF. The decrease in procarboxypeptidase U (TAFI) concentration in acute ischemic stroke correlates with stroke severity, evolution and outcome. J Thromb Haemost. 2010;8:75–80.
12. Brouns R, Sheorajpanday R, Kunnen J, De Surgeloose D, De Deyn PP. Clinical, biochemical and neuroimaging parameters after thrombolytic therapy predict long-term stroke outcome. Eur Neurol. 2009;62:9–15.
13. Brouns R, Sheorajpanday R, Wauters A, De Surgeloose D, Mariën P, De Deyn PP. Evaluation of lactate as a marker of metabolic stress and cause of secondary damage in acute ischemic stroke or TIA. Clin Chim Acta. 2008;397:27–31.
14. Brouns R, Marescau B, Possemiers I, Sheorajpanday R, De Deyn PP. Dimethylarginine levels in cerebrospinal fluid of hyperacute ischemic stroke patients are associated with stroke severity. Neurochem Res. 2009;34:1642–9.
15. Kehoe K, Brouns R, Verkerk R, Engelborghs S, De Deyn PP, Hendriks D, De Meester I. Prolyl carboxypeptidase activity decline correlates with severity and short-term outcome in acute ischemic stroke. Neurochem Res. 2015;40:81–8.
16. Birschel P, Ellul J, Barer D. Progressing stroke: towards an internationally agreed definition. Cerebrovasc Dis. 2004;17:242–52.
17. Matheeussen V, Lambeir A-M, Jungraithmayr W, Gomez N, Mc Entee K, Van der Veken P, Scharpé S, De Meester I. Method comparison of dipeptidyl peptidase IV activity assays and their application in biological samples containing reversible inhibitors. Clin Chim Acta. 2012;413:456–62.
18. Yang D, Nakajo Y, Iihara K, Kataoka H, Yanamoto H. Alogliptin, a dipeptidylpeptidase-4 inhibitor, for patients with diabetes mellitus type 2, induces tolerance to focal cerebral ischemia in non-diabetic, normal mice. Brain Res. 2013;1517:104–13.
19. Röhrborn D, Eckel J, Sell H. Shedding of dipeptidyl peptidase 4 is mediated by metalloproteases and up-regulated by hypoxia in human adipocytes and smooth muscle cells. FEBS Lett. 2014;588:3870–7.
20. Lamers D, Famulla S, Wronkowitz N, et al. Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome. Diabetes. 2011;60:1917–25.
21. Borlongan CV, Glover LE, Sanberg PR, Hess DC. Permeating the blood brain barrier and abrogating the inflammation in stroke: implications for stroke therapy. Curr Pharm Des. 2012;18:3670–6.
22. Nonaka N, Shioda S, Niehoff ML, Banks WA. Characterization of blood-brain barrier permeability to PYY3-36 in the mouse. J Pharmacol Exp Ther. 2003;306:948–53.
23. Kastin AJ, Akerstrom V. Nonsaturable entry of neuropeptide Y into brain. Am J Phys. 1999;276:E479–82.
24. Casrouge A, Decalf J, Ahloulay M, et al. Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV. J Clin Invest. 2011;121:308–17.
25. Olsen TS. Blood glucose in acute stroke. Expert Rev Neurother. 2009;9:409–19.
26. Jackson EK, Mi Z, Tofovic SP, Gillespie DG. Effect of dipeptidyl peptidase 4 inhibition on arterial blood pressure is context dependent. Hypertension. 2015;65:238–49.
27. Jacob M, Chang L, Puré E. Fibroblast activation protein in remodeling tissues. Curr Mol Med. 2012;12:1220–43.
28. Brokopp CE, Schoenauer R, Richards P, et al. Fibroblast activation protein is induced by inflammation and degrades type I collagen in thin-cap fibroatheromata. Eur Heart J. 2011;32:2713–22.